Specialty generic pharmaceutical company Lotus Pharmaceutical is set to see significant growth in sales of its high-margin leukemia drug in the U.S. this year, with peak shipments expected in Q2 and Q3. Another batch is scheduled for delivery in May and June, indicating strong Q2 operations. Eyeing the rapid growth of the Southeast Asian pharmaceutical market, Lotus Pharmaceutical plans to accelerate its expansion through acquisitions. Currently evaluating multiple acquisition opportunities related to products, sales, or manufacturing, the company aims to finalize at least one deal by the end of this quarter. Additionally, Lotus Pharmaceutical will decide by late June to July whether to proceed with the co-development of the NRX-101 bipolar disorder treatment.
Read more
